Review Article

Triple-Negative Breast Cancer: An Update on Neoadjuvant Clinical Trials

Table 2

Summary of neoadjuvant bevacizumab-based chemotherapy trials.*

Clinical trialsDesignDrugsPopulationStatuspCR rate

Gerber et al. [31] (GeparQuinto)Phase IIIArm 1: EC × 4 → D × 4
Arm 2: EC+ Bev × 4 → D + Bev × 4
TNBCCompletedArm 1: 96/342 (28%)
Arm 2: 119/327 (36.4%)

Bear et al. [14] (NSABP B-40)Phase III randomArm 1A-C: Anthracycline-taxane-based chemotherapy
Arm 2A-C: Anthracycline-taxane-based chemotherapy + Bev
HER2−Completed All Arms Bev: 203/588 (35%)
All Arms/no Bev: 168/592 (28%)
TNBC Bev: 121/236 (51%)
TNBC/no Bev: 115/243 (47%)
HR+ Bev: 82/352 (23%)
HR+/no Bev: 53/349 (15%)

CALGB-40603Phase II randomArm 1: T → AC
Arm 2: T + Bev → AC + Bev
Arm 3: T + Carbo → AC
Arm 4: T + Carbo + B → AC + Bev
TNBCOngoing

*TNBC: triple-negative breast cancer; pCR: pathological complete response; Bev: bevacizumab; T: paclitaxel; Carbo: carboplatin; D: docetaxel; C: cyclophosphamide; A: doxorubicin; E: epirubicin.